Altimmune Q3 net loss $22.8M; IMPACT enrollment done, FDA obesity plan set

Altimmune, Inc.

2024-Q3 EPS reported -$1.01 revenue$15,000

Net loss of $22.8M ($0.32/share) vs $20.7M ($0.39/share) in Q3 2023.
Cash, equivalents and short-term investments total $139.4M as of Sept 30, 2024.
Completed enrollment in Phase 2b IMPACT trial for MASH; top-line data expected Q2 2025.
FDA agreed on Phase 3 obesity program design; IND submissions for up to three additional indications planned.
Appointed Greg Weaver as CFO on November 11, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.